Castle Biosciences targets $345M-$355M 2026 revenue as TissueCypher volumes grow 58% and AdvanceAD-Tx reaches ~650 orders

Q1 2026 Management View "We delivered strong first quarter results, building on our momentum from 2025" (Founder, CEO, President & Director Derek Maetzold), adding that the company reported "revenue ...
Channel 3000

Washington Hilton attack spotlights hotel industry's nagging, costly security problems

Vulnerabilities include multiple access points, guests arriving at all hours, uneven screening and blurred lines around ...
The Manila Times

Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates

Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- ...

Micro-X advances key programs, delivers multiple milestones in March quarter

Special Report: Micro-X has reported a milestone-heavy March quarter, with progress across its Head CT clinical program, ...
Harvard Business Review

Should You Appoint an Interim CEO?

It’s riskier than you think. Here’s when it makes sense and who to choose. by Nicolas T. Deuschel, Robert Langan and Christoph Mât Your CEO just resigned. Or was fired. Or died. What now? Tomorrow you ...